Dexmedetomidine

For an informed discussion with your doctor or pharmacist. This information collection is not a clinically validated interaction checker. Missing data do not establish safety. Do not change or stop prescribed medicines on the basis of this information. The findings apply to the specific conditions studied; laboratory and animal studies cannot be directly extrapolated to humans.

Active substance: Dexmedetomidine

Examples of brand names: Dexdor [EU/DE]

ATC code: N05CM18

Main use (for orientation): Sedation

Documented research summary

Treatment of intoxication/withdrawal and multiple anaesthetic co-medications do not isolate a specific cannabinoid interaction.

Uncertainties and limitations

No controlled human CBD/THC–dexmedetomidine pharmacokinetic study found. The description as an antidote in an individual paediatric case abstract does not establish a general treatment recommendation.

Research is limited to the specified date and protocol; it is not globally exhaustive. Brand names and authorisations do not constitute a complete current market overview.

Structured assessment

Category: Drug context

Cannabinoid scope: 28 register names in the documented search family; neither 28 individual clinical trials nor a blanket assessment of all cannabinoids.

Evidence status: Insufficient pair-specific data

Mechanism / drug context: Dexmedetomidine: alpha-2 agonist, glucuronidation/CYP2A6, sedative cardiovascular effects.

Type of supporting material: Medicine information and documented individual review; no positive pair trial

Clinical interpretation: Requires individual assessment by a doctor or pharmacist. Lack of evidence does not establish safety; no dosage or discontinuation advice is provided.

Context: Dexmedetomidine hydrochloride, intravenous infusion preparation; active alpha-2 agonist, not a prodrug.

Drug context and gaps in search results are not measured interactions. The source role below describes which statement the source actually supports.

Source role [CA_L_D0157]: Drug context

Statement supported: Supports dosage form, metabolism and/or known risks; alone, it does not substantiate a cannabinoid–drug pair finding.

Source: DEXMEDETOMIDINE INJECTION, SOLUTION, CONCENTRATE DEXMEDETOMIDINE IN DEXTROSE (DEXMEDETOMIDINE) INJECTION [WG CRITICAL CARE, LLC] [CA_L_D0157]

Source role [CA_P_42366387]: Scope distinction / context

Statement supported: Clinical treatment context, not isolated cannabinoid–dexmedetomidine pharmacokinetics.

Source: Cannabidiol as an adjunct in refractory paroxysmal sympathetic hyperactivity following severe traumatic brain injury: a case report. [CA_P_42366387]

Source role [CA_P_34720146]: Scope distinction / context

Statement supported: Intoxication/withdrawal treatment rather than a controlled pair-specific study.

Source: Dexmedetomidine for Treatment of Delayed Peak Symptoms of Cannabis Withdrawal Syndrome: A Case Report. [CA_P_34720146]

Source role [CA_P_26138711]: Scope distinction / context

Statement supported: Treatment context; no unambiguously isolated cannabinoid-pair effect.

Source: A cannabinoid-intoxicated child treated with dexmedetomidine: a case report. [CA_P_26138711]

Source role [CA_P_39199820]: Scope distinction / context

Statement supported: Veterinary multiple-drug anaesthesia; no isolated dexmedetomidine-pair effect.

Source: Perioperative Analgesic and Sedative Effects of Cannabidiol in Cats Undergoing Ovariohysterectomy. [CA_P_39199820]

Scope of review: Individual research with documented title/abstract screening and targeted review of original sections. This is not exhaustive evidence that interactions are absent.

Unresolved source question: The complete stored individual review, label review, literature screening, conclusion and uncertainties were read. Targeted sections of original information were rechecked; no claim is made that all product information or full texts were completely revalidated.

Separately recorded findings

No separately substantiated finding for this drug–cannabinoid pair is recorded within the documented scope of review. This does not prove that no such study exists anywhere or that the combination is safe.

References and access status

[CA_L_D0157] DEXMEDETOMIDINE INJECTION, SOLUTION, CONCENTRATE DEXMEDETOMIDINE IN DEXTROSE (DEXMEDETOMIDINE) INJECTION [WG CRITICAL CARE, LLC]

Original source / bibliographic reference

Authors: WG Critical Care, LLC

Year: 2026

Source type: Current published human-use SPL / product information

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

[CA_P_42366387] Cannabidiol as an adjunct in refractory paroxysmal sympathetic hyperactivity following severe traumatic brain injury: a case report.

Original source / bibliographic reference

Authors: Swamiyappan SS, Reddy JK, Ramesh R, Sivaji H, Visvesvaran V.

Year: 2026

Source type: Journal Article; Case Reports; case-report

DOI: 10.1186/s13256-026-06284-5

PMID: 42366387

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_34720146] Dexmedetomidine for Treatment of Delayed Peak Symptoms of Cannabis Withdrawal Syndrome: A Case Report.

Original source / bibliographic reference

Authors: MacCamy K, Hu D.

Year: 2021

Source type: research-article; Journal Article

DOI: 10.1177/0018578720919025

PMID: 34720146

Source access – 23 October 2026: Automated direct retrieval was restricted; this does not establish that the link is broken.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

PubMed Central – full-text access according to the literature database – Archive attribution confirmed by Europe PMC metadata. Direct retrieval was not fully verified here; access may require a browser check.

Europe PMC – full-text access according to the literature database – Listed as freely available HTML full text in the official Europe PMC metadata. Direct retrieval was not fully verified here.

[CA_P_26138711] A cannabinoid-intoxicated child treated with dexmedetomidine: a case report.

Original source / bibliographic reference

Authors: Cipriani F, Mancino A, Pulitanò SM, Piastra M, Conti G.

Year: 2015

Source type: Journal Article; Case Reports; case-report

DOI: 10.1186/s13256-015-0636-2

PMID: 26138711

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

[CA_P_39199820] Perioperative Analgesic and Sedative Effects of Cannabidiol in Cats Undergoing Ovariohysterectomy.

Original source / bibliographic reference

Authors: Zanelli GR, Vieira GBM, Souza RVM, Aguiar AJA, Cassu RN.

Year: 2024

Source type: research-article; Journal Article

DOI: 10.3390/ani14162286

PMID: 39199820

Source access – 23 October 2026: Source destination was accessible when checked.

Bibliographic attribution or source identity cross-checked.

DOI – publisher access (access restrictions may apply)

Research as of 23 October 2026. Not all original full texts could be reviewed in full. Source accessibility and the strength of scientific evidence must be assessed separately. An accessible link does not establish medical approval; a bibliographic record with an abstract does not replace the original full text.

Drug search and explanation of the evidence · Guide: cannabinoids and medicines · Author and responsibility